Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials

While current lymphoma therapies induce remission in most dogs, drug‐resistant relapse is common, creating a need for novel agents. Rabacfosadine (RAB), a double prodrug of the acyclic nucleotide phosphonate 9‐(2‐phosphonylmethoxyethel) guanine (PMEG), preferentially targets lymphoma cells with redu...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Vet Comp Oncol
Hlavní autoři: Saba, Corey F., Clifford, Craig, Burgess, Kristine, Phillips, Brenda, Vail, David, Wright, Zachary, Curran, Katie, Fan, Timothy, Elmslie, Robyn, Post, Gerald, Thamm, Douglas
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Publishing Ltd 2020
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7754483/
https://ncbi.nlm.nih.gov/pubmed/32346934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/vco.12605
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky